Trial · NCT07877077

HYAcorp MLF1 Hyaluronic Acid Filler for Penile Girth Enhancement

NCT07877077, Not applicable, Not yet recruiting, Biruni University

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. HYAcorp MLF1 Hyaluronic Acid Filler for Penile Girth Enhancement. Trials, record NCT07877077. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877077

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: HYAcorp MLF1 Hyaluronic Acid Filler for Penile Girth Enhancement
NCT number: NCT07877077
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 65 participants, estimated
Lead sponsor: Biruni University
Conditions: Penile Girth Enhancement
Interventions: cross-linked hyaluronic acid
First posted: 2026-10-16
Last updated: 2026-10-16

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Average Flaccid Penile Circumference at Month 6	Baseline and Month 6	Flaccid penile circumference will be measured in millimeters at the distal, middle, and proximal penile shaft using a non-stretch measuring tape under standardized conditions. The arithmetic mean of the three measurements will be recorded as the average flaccid penile circumference. Change will be calculated as the Month 6 value minus the baseline value.
Secondary	Change From Baseline in Average Flaccid Penile Circumference at Other Follow-up Time Points	Baseline, immediately after treatment, Month 3, and Month 12	Average flaccid penile circumference will be calculated as the arithmetic mean of distal, middle, and proximal shaft circumference measurements. Change at each follow-up time point will be calculated as the follow-up value minus the baseline value and reported in millimeters.
Secondary	Participant-Reported Residual Filler Durability Score	Month 3, Month 6, and Month 12	Participants will estimate the amount of residual filler using a 5-level ordinal scale: 0=no residual filler, 1=approximately 25% remaining, 2=approximately 50% remaining, 3=approximately 75% remaining, and 4=approximately 100% remaining. Higher scores indicate greater perceived filler durability.
Secondary	Change From Baseline in Penile Appearance Satisfaction Score	Baseline, Month 3, Month 6, and Month 12	Penile appearance satisfaction will be rated on a 5-point ordinal scale: 1=very dissatisfied, 2=dissatisfied, 3=neutral, 4=satisfied, and 5=very satisfied. Higher scores indicate greater satisfaction. Change will be calculated as the follow-up score minus the baseline score.
Secondary	Change From Baseline in Sexual Life Satisfaction Score	Baseline, Month 3, Month 6, and Month 12	Sexual life satisfaction will be rated on a 5-point ordinal scale: 1=very dissatisfied, 2=dissatisfied, 3=neutral, 4=satisfied, and 5=very satisfied. Higher scores indicate greater satisfaction. Change will be calculated as the follow-up score minus the baseline score.
Secondary	Change From Baseline in International Index of Erectile Function-5 (IIEF-5) Score	Baseline, Month 3, Month 6, and Month 12	Erectile function will be assessed using the validated 5-item International Index of Erectile Function (IIEF-5). The total score ranges from 5 to 25, with higher scores indicating better erectile function and therefore a better outcome. Change from baseline will be calculated as the follow-up score minus the baseline score.
Secondary	Change From Baseline in Premature Ejaculation Diagnostic Tool (PEDT) Score	Baseline, Month 3, Month 6, and Month 12	Ejaculatory function will be assessed using the validated 5-item Premature Ejaculation Diagnostic Tool (PEDT). Total scores range from 0 to 20, with higher scores indicating a greater likelihood or severity of premature ejaculation. Change will be calculated as the follow-up score minus the baseline score.
Secondary	Number of Participants With Adverse Events Through Month 12	From treatment through Month 12	Adverse events will be recorded according to onset, severity, relationship to treatment, and outcome. The number and proportion of participants experiencing adverse events will be summarized. Serious adverse events will be reported separately and described narratively.
Secondary	Inter-rater Reliability of Penile Circumference Measurements Assessed by Intraclass Correlation Coefficient	Month 12	Agreement between two independent evaluators will be assessed using a two-way random-effects, absolute-agreement intraclass correlation coefficient \[ICC(2,1)\] with a 95% confidence interval.
Secondary	Proportion of Participants Lost to Follow-up by Month 12	From enrollment through Month 12	The number and proportion of enrolled participants who do not complete the planned follow-up through Month 12 will be reported.

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
30833149	BACKGROUND	PubMed
31735613	BACKGROUND	PubMed
32260508	BACKGROUND	PubMed
33533738	BACKGROUND	PubMed
33988002	BACKGROUND	PubMed
34297894	BACKGROUND	PubMed
37663705	BACKGROUND	PubMed
38777188	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07877077

GET https://conductscience.org/api/trials/v1/NCT07877077/registered

API reference For AI assistants